Last reviewed · How we verify
Aminoguanidine
Aminoguanidine is a Small molecule drug developed by University of Minnesota. It is currently in Phase 1 development. Also known as: AG, Inhalation of aminoguanidine, Nebulased Aminoguanidine.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Aminoguanidine |
|---|---|
| Also known as | AG, Inhalation of aminoguanidine, Nebulased Aminoguanidine |
| Sponsor | University of Minnesota |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects (NA)
- NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD (NA)
- Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients (PHASE1)
- Effect of Selective iNOS Inhibition During Human Endotoxemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminoguanidine CI brief — competitive landscape report
- Aminoguanidine updates RSS · CI watch RSS
- University of Minnesota portfolio CI
Frequently asked questions about Aminoguanidine
What is Aminoguanidine?
Who makes Aminoguanidine?
Is Aminoguanidine also known as anything else?
What development phase is Aminoguanidine in?
Related
- Manufacturer: University of Minnesota — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: AG, Inhalation of aminoguanidine, Nebulased Aminoguanidine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing